Wall Street Zen Upgrades Maplight Therapeutics (NASDAQ:MPLT) to Sell

Posted by Brenda Bartman on Aug 17th, 2026

Maplight Therapeutics (NASDAQ:MPLT – Get Free Report) was upgraded by analysts at Wall Street Zen from a “strong sell” rating to a “sell” rating in a research note issued on Saturday.

MPLT has been the topic of a number of other research reports. HC Wainwright cut their price target on shares of Maplight Therapeutics from $45.00 to $26.00 and set a “buy” rating on the stock in a report on Tuesday, July 28th. Morgan Stanley reaffirmed an “equal weight” rating and issued a $21.00 price objective (down from $34.00) on shares of Maplight Therapeutics in a research note on Tuesday, July 28th. Raymond James Financial set a $31.00 price objective on shares of Maplight Therapeutics in a research report on Friday. Stifel Nicolaus boosted their target price on shares of Maplight Therapeutics from $28.00 to $36.00 and gave the company a “buy” rating in a research note on Monday, June 1st. Finally, Benchmark restated a “buy” rating on shares of Maplight Therapeutics in a report on Monday, June 22nd. Four equities research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $29.67.

Get Our Latest Analysis on Maplight Therapeutics

Maplight Therapeutics Stock Performance

Shares of MPLT opened at $11.75 on Friday. The business’s 50-day moving average price is $27.31 and its 200 day moving average price is $24.53. The stock has a market capitalization of $500.76 million and a P/E ratio of -0.28. Maplight Therapeutics has a 1-year low of $9.10 and a 1-year high of $40.43.

Maplight Therapeutics (NASDAQ:MPLT – Get Free Report) last posted its quarterly earnings data on Thursday, August 13th. The company reported ($1.32) EPS for the quarter, beating analysts’ consensus estimates of ($1.40) by $0.08. On average, research analysts predict that Maplight Therapeutics will post -5.22 earnings per share for the current year.

Insider Buying and Selling

In related news, Director Troy Cox purchased 15,620 shares of the stock in a transaction dated Tuesday, July 28th. The shares were acquired at an average cost of $9.52 per share, for a total transaction of $148,702.40. Following the acquisition, the director directly owned 15,620 shares in the company, valued at approximately $148,702.40. The trade was a ∞ increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider James Woodruff Lillie sold 22,082 shares of the company’s stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $12.54, for a total transaction of $276,908.28. Following the completion of the transaction, the insider directly owned 202,380 shares in the company, valued at $2,537,845.20. This trade represents a 9.84% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 3.80% of the stock is owned by corporate insiders.

Institutional Trading of Maplight Therapeutics

A number of institutional investors have recently bought and sold shares of the company. Legal & General Group Plc acquired a new position in Maplight Therapeutics in the 2nd quarter worth about $37,000. Strs Ohio purchased a new stake in shares of Maplight Therapeutics during the 4th quarter worth about $53,000. Police & Firemen s Retirement System of New Jersey acquired a new stake in shares of Maplight Therapeutics during the 4th quarter valued at about $70,000. New York State Common Retirement Fund acquired a new stake in shares of Maplight Therapeutics during the 4th quarter valued at about $93,000. Finally, MetLife Investment Management LLC bought a new stake in shares of Maplight Therapeutics in the 4th quarter valued at approximately $172,000.

About Maplight Therapeutics

(Get Free Report)

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.